Scilex Holding Company
NASDAQ:SCLXDrug Manufacturers - General
-$0.17 today
- Market cap
- $53.83M
- Beta
- 1.71
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$60.90
Volume 0.00M
Average 0.13M
SCLX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Scilex Holding CompanyNASDAQ: SCLX
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 70394.3% from a year ago
Other current liabilities stood at $308.06M at the end of Q1 FY2026, up 70394.3% from a year earlier and up 2.1% from the prior quarter. Over 3 fiscal years it compounded at +945.6% a year.
Context
- Other current liabilities amounted to 104.9% of total assets at the end of Q1 FY2026, up 104.4 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +70394.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 301.79M USD
- Year-over-year change
- +78.5%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 301.79M | +78.5% |
| FY2024 | 2024-12-31 | 169.04M | +34328.5% |
| FY2023 | 2023-12-31 | 491K | +86.0% |
| FY2022 | 2022-12-31 | 264K | — |
| FY2021 | 2021-12-31 | 0 | — |
Other Current Liabilities vs competitors
How SCLX compares with its peers on the latest reported figures
- SCLX's Mar 2026 other current liabilities of $308.06M is the highest of the 9 companies compared; the peer median is $3.56M.
- Its year-over-year change of +70394.3% is the highest of 8, against a peer median of -8.9%.
- Other current liabilities amounts to 104.9% of total assets for SCLX, versus a peer median of 6.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $308.06M | +70394.3% | +945.6% | 104.9% | |
| Mar 2026 | $28.15M | -74.2% | -6.4% | 15.1% | |
| Mar 2026 | $27.02M | +70.3% | +34.0% | 54.3% | |
CTORCitius Oncology, Inc. | Mar 2026 | $25.87M | -8.9% | — | 25.7% |
IRDOpus Genetics, Inc. | Mar 2026 | $4.12M | -67.6% | — | 6.2% |
| Mar 2026 | $3M | +101.8% | -3.9% | 1.1% | |
| Mar 2026 | $2.2M | — | -28.3% | 6.5% | |
| Mar 2026 | $1.61M | +24.3% | +218.8% | 1.2% | |
| Mar 2026 | $0 | -100.0% | +24.1% | 0.0% | |
| Peer median (excluding SCLX) | $3.56M | -8.9% | +10.1% | 6.3% | |
Competitors are the stored peer set for SCLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 4.34M | 2.18M | 3.92M | 3.27M | 4.96M |
| Short-term Investments | 0 | 0 | 0 | 0 | 6.03M |
| Net Receivables | 14.27M | 21.24M | 34.6M | 26.44M | 15.24M |
| Inventory | 2.56M | 1.38M | 4.21M | 2.44M | 4.79M |
| Other Current Assets | 1.83M | 0 | 0 | 9.4M | 7.34M |
| Total Current Assets | 23M | 29.61M | 46.78M | 41.55M | 38.36M |
| Property, Plant & Equipment (Net) | 2.11M | 1.9M | 3.67M | 2.93M | 28.42M |
| Goodwill | 13.48M | 13.48M | 13.48M | 13.48M | 13.48M |
| Intangible Assets | 38.8M | 40.59M | 36.49M | 32.45M | 59.09M |
| Long-term Investments | 0 | 0 | 808K | 2.42M | 1M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 538K | 944K | 89K | 119K | 224.64M |
| Total Non-current Assets | 54.93M | 56.92M | 54.53M | 51.41M | 326.62M |
| Total Assets | 77.93M | 86.53M | 101.31M | 92.95M | 364.98M |
| Account Payables | 4.28M | 8.45M | 40.95M | 52.62M | 86.27M |
| Short-term Debt | 57.56M | 0 | 108.43M | 34.88M | 92.28M |
| Tax Payables | 0 | 0 | 1.45M | 876K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 264K | 491K | 169.04M | 301.79M |
| Total Current Liabilities | 169.42M | 44.84M | 250.38M | 259.64M | 483.65M |
| Long-term Debt | 95.54M | 0 | 17.04M | 845K | 27.12M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 5.19M | 0 | 0 | 2.69M | 0 |
| Other Non-current Liabilities | 30.51M | 4.78M | 4.59M | 20.91M | 52.81M |
| Total Non-current Liabilities | 132.39M | 5.45M | 23.87M | 25.96M | 93.08M |
| Total Liabilities | 301.81M | 50.29M | 274.25M | 285.59M | 576.73M |
| Common Stock | 13K | 14K | 16K | 24K | 1K |
| Retained Earnings | (352.55M) | (375.91M) | (490.25M) | (563.05M) | (921.79M) |
| Accumulated OCI | 0 | (0) | 0 | 6.32M | (5.8M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | (3.97M) |
| Total Equity | (223.88M) | 36.24M | (172.94M) | (192.64M) | (211.75M) |
| Total Debt | 154.75M | 1.41M | 128.46M | 37.96M | 132.54M |
| Net Debt | 150.41M | (774K) | 124.54M | 34.69M | 127.59M |
Scilex Holding Company
NASDAQ:SCLX
Intrinsic Alpha fair value
Locked
Current Price
$6.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.